⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 9, 2024Neurology

Effects of Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa on Sleep Dysfunction in People with Parkinson’s (P9-3.005)

Robert A. Hauser Bruno Bergmans Irene A. Malaty Daniel Cobb Jaclyn Homola Lars Bergmann Resmi Gupta Jia Jia Megha Shah К. Ray Chaudhuri

View at Publisher

Ask AI

Bookmark

Share

Abstract

Assess whether 24-hour/day continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa (LDp/CDp) improves Parkinson's Disease Sleep Scale-2 (PDSS-2) subdomains in people with Parkinson's (PwP).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hauser et al. (2024) studied this question.

synapsesocial.com/papers/68e6fcafb6db643587676bfb https://doi.org/10.1212/wnl.0000000000205314

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson’s disease: Considerations for initiation and maintenanceClinical Trial · 2024 · 42 citations
2Continuous subcutaneous foslevodopa/foscarbidopa infusion for advanced parkinson’s diseaseLate-Phase Clinical Trial · 2026
3Foslevodopa/Foscarbidopa Overnight Administration Improves Nocturia in Patients with Parkinson's Disease: Evidence from a Real‐World StudyOriginal Research · 2026 · 1 citations
4Real-world Tolerability of Foslevodopa/Foscarbidopa Subcutaneous Infusion in Parkinson’s Disease: Discontinuation Beyond Titration (S26.006)Early-Phase Clinical Trial · 2026
5Continuous Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson's DiseaseObservational Study · 2026 · 1 citations

Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/Foscarbidopa2024
Living with Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa for Symptom Management in Advanced Parkinson’s Disease: A Patient Experience Study (P9-3.006)2024
Long-term Safety and Tolerability of Foslevodopa/Foscarbidopa for Treatment of Motor Fluctuations in Parkinson’s Disease (P9-3.008)2024
Differences in Epilepsy Etiology, Type, Syndrome, and Severity Between Māori and Non-Māori-Non-Pasifika Children With Epilepsy in New ZealandNeurology · 2026
Teaching NeuroImage: Opioid-Associated Amnestic SyndromeNeurology · 2026

More from Neurology